OC
HRMY icon

Oakworth Capital’s Harmony Biosciences HRMY Stock Holding History

Oakworth Capital’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,809
Closed -$404K – 866
2025
Q4 		$404K Hold
10,809
– – 0.02% 153
2025
Q3 		$298K Sell
10,809
-318
-3% -$11K 0.02% 186
2025
Q2 		$352K Hold
11,127
– – 0.02% 153
2025
Q1 		$369K Hold
11,127
– – 0.03% 144
2024
Q4 		$383K Buy
11,127
+1,452
+15% +$49.9K 0.03% 146
2024
Q3 		$387K Hold
9,675
– – 0.03% 145
2024
Q2 		$292K Hold
9,675
– – 0.02% 159
2024
Q1 		$325K Buy
9,675
+5,107
+112% +$164K 0.02% 157
2023
Q4 		$148K Hold
4,568
– – 0.01% 216
2023
Q3 		$150K Buy
+4,568
New +$159K 0.01% 199

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Oakworth Capital's HRMY Position: Q1 2026 in Review

Oakworth Capital sold out of Harmony Biosciences (HRMY) in Q1 2026, closing a stake of 10,809 shares — an estimated $404K sold.

Oakworth Capital first reported a position in HRMY in Q3 2023 and held it in 10 quarters. The position peaked at $404K in Q4 2025. 309 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

  • Oakworth Capital reported no remaining Harmony Biosciences position as of Q1 2026 after selling out during the quarter.
  • Oakworth Capital sold 10,809 Harmony Biosciences shares in Q1 2026, an estimated $404K.
  • Oakworth Capital first reported a position in Harmony Biosciences in Q3 2023 and held it in 10 quarters.
  • Oakworth Capital's Harmony Biosciences position peaked at $404K in Q4 2025.
  • 309 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Oakworth Capital's 13F filing for Q1 2026, filed 24 Apr 2026.